All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Study Intervention and comparison (in HF clinic unless stated otherwise) Population Outcomes Comments n=76 renal failure atrial fibrillation ventricular arrhythmia NP monitoring: Therapy increased if NT-proBNP No protocol: No treatment algorithm reported, 11 months Age mean: 73(8) NYHA I/II/III/IV HTA IPD: Mortality by age all-cause admission by age Recruited SIGNAL-HF trial: NP monitoring (in primary care): Treatment increased to achieve target (NT-proBNP reduction of 50% from baseline), 9 months Clinical monitoring (in primary care): Therapy increased at clinician s discretion according to clinical assessment, 9 months Age mean: 78(7) NYHA class II-IV, LVEF < 50%, stable in primary care Elevated NPs (NT- proBNP levels males > 800, females > 1000 ng/L) HTA aggregate: Mortality by age Troughton IPD: HF admission Study papers: Quality of life Recruited from primary STARS-BNP trial: Jourdain NP monitoring: Therapy intensified to reach target Clinical monitoring: Therapy intensified at clinician discretion according to clinical assessment, 15 months Age > 18 years NYHA class II/III, LVEF < 45% No admission or change of medication in last month, optimal medical treatment with diuretics, ACEi/ARB and BB HTA aggregate: Mortality by age Troughton IPD: HF admission Study papers: Renal function Recruited from clinics TIME-CHF trial: (Pfisterer , Brunner-la , Sanders-van , Sanders-van , Kaufmann ) NP monitoring: Therapy intensified to reach BNP target n=251 with rEF, 59 with pEF Clinical monitoring: Therapy intensified to reach target (NYHA II), 18 months n=248 with rEF, 64 with pEF Age 60 years, mean: NYHA class II with current therapy, HF admission in the last year, elevated NPs (NT- proBNP of 400pg/mL if < pg/mL if 75y) HTA aggregate: Mortality by age all-cause admission by age Study papers: Quality of life Hypotension Bradycardia renal failure hyperkalaemia Recruited from multiple centres in Switzerlan d and Germany Chronic Heart Failure Monitoring NICE 2018. 